

FORM PTO 1390 (REV 5-93)		US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NUMBER 2005_0741A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371			U.S. APPLICATION NO. (if known, see 37 CFR 1.57) NEW 333806
International Application No. PCT/JP2003/014119	International Filing Date November 5, 2003	Priority Date Claimed November 6, 2002	
Title of Invention PYRAZOLONAPHTHYRIDINE DERIVATIVES			
Applicant(s) For DO/EO/US Hashime KANAZAWA, Tomoji AOTSUKA, Kentarou KUMAZAWA, Kouki ISHITANI, Takashi NOSE			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). ATTACHMENT A</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19.</p> <p>9. <input checked="" type="checkbox"/> An executed oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT B</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).</p> <p>Items 11. to 14. below concern other document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ATTACHMENT C</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p style="margin-left: 40px;">ATTACHMENT D</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. ATTACHMENT E</p> <p style="margin-left: 40px;"><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input checked="" type="checkbox"/> Other items or information: WO 2004/041819 - ATTACHMENT F</p>			

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. NEW 107533806		INTERNATIONAL APPLICATION NO. PCT/JP2003/014119		ATTORNEY'S DOCKET NO. 2005_0741A							
15. [X] The following fees are submitted Basic National Stage Fee \$300.00 National Stage Search Fee \$400.00 National Stage Examination Fee \$200.00 Specification/drawings in excess of 100 pages (1 units of 50 x \$250.00) = \$250.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:50%;">CALCULATIONS</th> <th style="width:50%;">PTO USE ONLY</th> </tr> <tr> <td colspan="2" style="height: 40px;"></td> </tr> <tr> <td>\$1,150.00</td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY			\$1,150.00	
CALCULATIONS	PTO USE ONLY										
\$1,150.00											
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$							
Claims	Number Filed	Number Extra	Rate								
Total Claims	24 -20 =	4	X \$50.00	\$200.00							
Independent Claims	2 - 3 =	4	X \$200.00	\$							
Multiple dependent claim(s) (if applicable)			+ \$360.00	\$							
TOTAL OF ABOVE CALCULATIONS =				\$1,350.00							
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$							
SUBTOTAL =				\$1,350.00							
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$						
TOTAL NATIONAL FEE =				\$1,350.00							
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$40.00							
TOTAL FEES ENCLOSED =				\$1,390.00							
				Amount to be refunded	\$						
				Amount to be charged	\$						
a. [X] A check in the amount of \$1,390.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
19. CORRESPONDENCE ADDRESS <div style="text-align: center; margin-top: 20px;"> CUSTOMER NO. 000513 </div>			By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367 WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250 <div style="text-align: right;">May 5, 2005</div>								

[CHECK NO. 68100]

[2005_0741A]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE INTERNATIONAL
APPLICATION OF:

Hashime KANAZAWA, et al.

10/533806

JC17 Rec'd PCT/PTO 05 MAY 2005

INTERNATIONAL SERIAL NO: PCT/JP03/14119

INTERNATIONAL FILING DATE: 05.11.03

FOR: PYRAZOLONAPHTHYRIDINE DERIVATIVES

Verification of Translation

Honorable Commissioner of Patents & Trademarks
Washington, D.C. 20231

Sir:

Akinobu MIZUNO, a translator of Lions Mansion
Shibuya Dogenzaka 303, 22-12, Maruyama-cho, Shibuya-ku,
Tokyo 150-0044 Japan

declares:

1) that he knows well both the Japanese and English
languages;

2) that he translated the above-identified International
Application from Japanese to English;

3) that the attached English translation is a true and
correct translation of the above-identified International
Application to the best of his knowledge and belief; and

4) that all statements made of his own knowledge are
true and that all statements made on information and belief
are believed to be true, and further that these statements
are made with the knowledge that willful false statements and
the like are punishable by fine or imprisonment, or both,
under Section 1001 of Title 18 of the United States Code and
that such false statements may jeopardize the validity of the
application or any patent issuing thereon.

Date:

April 26, 2005

By:


AKINOBU MIZUNO

ATTACHMENT A